Adesuyi Ayodeji Omoare

Dr. Adesuyi Ayodeji Omoare

Nigeria Centre for Disease Control, Abuja, Federal Capital Territory, Nigeria
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
IOIdowu Bolade Olawoye
Idowu Bolade Olawoye
POPaul Oluniyi
Paul Oluniyi
JOJudith Oguzie
Judith Oguzie
JUJessica N. Uwanibe
Jessica N. Uwanibe
AKAdeyemi Kayode
Adeyemi Kayode
THT. Happi
T. Happi
Identifying the dissemination patterns and impacts of a virus of economic or health importance during a pandemic is crucial, as it informs the public on policies for containment in order to reduce the spread of the virus. In this study, we integrated genomic and travel data to investigate the emergence and spread of the SARS-CoV-2 B.1.1.318 and B.1.525 (Eta) variants of interest in Nigeria and the wider Africa region. By integrating travel data and phylogeographic reconstructions, we find that these two variants that arose during the second wave in Nigeria emerged from within Africa, with the B.1.525 from Nigeria, and then spread to other parts of the world. Data from this study show how regional connectivity of Nigeria drove the spread of these variants of interest to surrounding countries and those connected by air-traffic. Our findings demonstrate the power of genomic analysis when combined with mobility and epidemiological data to identify the drivers of transmission, as bidirectional transmission within and between African nations are grossly underestimated as seen in our import risk index estimates.

17 June 2022 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
RARosemary A. Audu
Rosemary A. Audu
KSKristen A. Stafford
Kristen A. Stafford
LSLaura Steinhardt
Laura Steinhardt
ZMZaidat A. Musa
Zaidat A. Musa
NINnaemeka Iriemenam
Nnaemeka Iriemenam
FGfor the Nigeria SARS-CoV-2 Survey Group
for the Nigeria SARS-CoV-2 Survey Group
The observed epidemiology of SARS-CoV-2 in sub-Saharan Africa has varied greatly from that in Europe and the United States, with much lower reported incidence. Population-based studies are needed to estimate true cumulative incidence of SARS-CoV-2 to inform public health interventions. This study estimated SARS-CoV-2 seroprevalence in four selected states in Nigeria in October 2020. We implemented a two-stage cluster sample household survey in four Nigerian states (Enugu, Gombe, Lagos, and Nasarawa) to estimate age-stratified prevalence of SARS-CoV-2 antibodies. All individuals in sampled households were eligible for interview, blood draw, and nasal/oropharyngeal swab collection. We additionally tested participants for current/recent malaria infection. Seroprevalence estimates were calculated accounting for the complex survey design. Across all four states, 10,629 (96·5%) of 11,015 interviewed individuals provided blood samples. The seroprevalence of SARS-CoV-2 antibodies was 25·2% (95% CI 21·8–28·6) in Enugu State, 9·3% (95% CI 7·0–11·5) in Gombe State, 23·3% (95% CI 20·5–26·4) in Lagos State, and 18·0% (95% CI 14·4–21·6) in Nasarawa State. Prevalence of current/recent malaria infection ranged from 2·8% in Lagos to 45·8% in Gombe and was not significantly related to SARS-CoV-2 seroprevalence. The prevalence of active SARS-CoV-2 infection in the four states during the survey period was 0·2% (95% CI 0·1–0·4). Approximately eight months after the first reported COVID-19 case in Nigeria, seroprevalence indicated infection levels 194 times higher than the 24,198 officially reported COVID-19 cases across the four states; however, most of the population remained susceptible to COVID-19 in October 2020.

Verified
Journal Article
Open access
PDF file
OAOluwaseyi Sedowhe Ashaka
Oluwaseyi Sedowhe Ashaka
AOAdesuyi Ayodeji Omoare
Adesuyi Ayodeji Omoare
AJAyorinde James
Ayorinde James
OAOluwapelumi Olufemi Adeyemi
Oluwapelumi Olufemi Adeyemi
FOFemi Oladiji
Femi Oladiji
OAOlajide Olubunmi Agbede
Olajide Olubunmi Agbede
Regional variations exist in HPV prevalence worldwide despite reports of high prevalence rates among African women. Limited data on genital HPV prevalence necessitated this study with the aim of determining the prevalence of genital HPV and associated risk factors among women in Lagos, Nigeria. Exfoliated cervical cells were collected with consent from 165 women using a cervical brush. Viral DNA was extracted and amplified by nested PCR using two sets of consensus primers (MY09/11 and GP5+/6+). An unconditional logistic regression model was used to identify predictors of HPV positivity. The HPV prevalence was 81.82% in all women and 87.59% in women with normal cytology. The risk of HPV infection was significantly increased among women who had a history of STI (odds ratio (OR) 3.94; 95% confidence interval (CI): 1.51–10.25, p = 0.005) while there was a significantly reduced risk of HPV infection among those who used condoms (odds ratio (OR) 3.94; 95% confidence interval (CI): 0.18–0.91, p = 0.03). The HPV prevalence observed shows an increased transmission of the virus in Lagos, Nigeria. Therefore, there is a need for intense public awareness and the implementation of early detection tests, treatment, and vaccination to prevent an increase in cervical cancer cases in Lagos, Nigeria.

12 July 2024 in Acta Elit Salutis
Verified
Journal Article
Open access
SESeyi Samson Enitan
Seyi Samson Enitan
KAKirellos Said Abbas
Kirellos Said Abbas
RERawan Raad Hassan Elrufai
Rawan Raad Hassan Elrufai
SUSolomon Umukoro
Solomon Umukoro
CTCausette Laura Metago Tsague
Causette Laura Metago Tsague
COChisom Blossom Onyeji
Chisom Blossom Onyeji
Dengue Fever remains a pressing public health concern in the Global South, including in Africa, where limited resources, inadequate surveillance, weak health systems, climate change, and urbanization exacerbate the threat. This review study focuses on strategies to strengthen preparedness, capacity building efforts on surveillance, vector control, health system strengthening, community engagement, and research. Investing in training programs, research initiatives, and regional collaboration is vital. Advocacy for increased political commitment and resource allocation is necessary to drive policy support. African nations are actively contributing to global Dengue control efforts, showcasing resilience amidst adversity. There are promising prospects for improvement. Enhanced surveillance, capacity building, community engagement, research, and regional collaboration are identified as crucial strategies. Strengthening surveillance systems can provide accurate data for targeted interventions, while investing in healthcare infrastructure and training can improve diagnosis and treatment capabilities. Community engagement and education efforts can promote preventive behaviours, and research initiatives drive progress in Dengue prevention and control. Additionally, regional collaboration fosters knowledge exchange and resource sharing. By addressing these challenges and capitalizing on emerging opportunities, Africa can further strengthen its contribution to global Dengue control efforts. Through sustained investment, collaboration, and innovation, Africa has the potential to mitigate Dengue's impact and inspire similar efforts worldwide. Advocacy for increased political commitment and resource allocation is essential to drive policy support. By prioritizing Dengue control and implementing sustainable interventions tailored to local contexts, Africa can enhance public health resilience and contribute significantly to the global fight against Dengue.

28 December 2024 in Avicenna Journal of Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
SESeyi Samson Enitan
Seyi Samson Enitan
RARichard Yomi Akele
Richard Yomi Akele
AOAdesuyi Ayodeji Omoare
Adesuyi Ayodeji Omoare
BDBanenat Dogonyaro
Banenat Dogonyaro
MIMichael Unata Iduh
Michael Unata Iduh
TATemitayo Oluwatomisin Ajayi
Temitayo Oluwatomisin Ajayi
Mpox, declared a Public Health Emergency of International Concern by the World Health Organization (WHO), poses a growing global threat. The resurgence, driven by the highly transmissible and severe clade Ib strain from the Democratic Republic of the Congo, raises concerns about a potential pandemic. This narrative review aims to identify actionable strategies to mitigate the current Mpox outbreak by leveraging lessons from past health crises, particularly COVID-19, and to highlight future research priorities essential for global preparedness. A comprehensive literature review from 2018 to 2024 was conducted using Google Scholar, Scopus, and PubMed databases, focusing on Mpox transmission, vaccine efficacy, antiviral treatments, and public health responses. Our findings revealed that the resurgence of Mpox is fueled by viral evolution, ecological changes, and inadequate surveillance, exacerbated by inequitable healthcare access and insufficient public health infrastructure. While existing vaccines, such as Jynneos and ACAM2000, offer protection, their long-term efficacy and safety across diverse populations require further study. Antiviral treatments, including tecovirimat and brincidofovir, show promise but lack optimized care protocols and face challenges such as emerging resistance. Lessons from the COVID-19 response underscore the importance of enhancing global surveillance systems, strengthening healthcare infrastructure, ensuring equitable vaccine distribution, and fostering community engagement. Effective Mpox management also requires standardized treatment guidelines and the integration of genomic monitoring to track viral evolution and drug resistance. Urgent international collaboration is needed to avert a potential Mpox pandemic. Priorities include advancing research on long-term vaccine efficacy, optimizing antiviral therapies, and improving care for severe cases. Actionable recommendations include robust policies, sustainable funding, and global collaboration to strengthen pandemic preparedness and mitigate Mpox’s impact.

6 July 2025 in Jordan Medical Journal
Verified
Journal Article
Closed access
MDMichael Dada
Michael Dada
SESeyi Enitan
Seyi Enitan
RARichard Akele
Richard Akele
OEOkeoghene Edafetanure-Ibeh
Okeoghene Edafetanure-Ibeh
AOAdesuyi Ayodeji Omoare
Adesuyi Ayodeji Omoare
FEFaith Edafetanure-Ibeh
Faith Edafetanure-Ibeh
Background: Mpox (formerly monkeypox) has emerged as a critical public health issue worldwide, characterized by notable differences in acquisition and disease severity between Africa and the Americas. Understanding the interplay of behavioral, virologic, and immunologic factors is essential to addressing these disparities. Aim: This review examines the behavioral, virologic, and immunologic determinants influencing Mpox acquisition and severity, with a focus on regional variations in Africa and the Americas. Methodology: A narrative review was conducted using peer-reviewed articles, public health reports, and official guidelines published between 2019 and 2024. Key sources were identified via databases including PubMed, Scopus, and Google Scholar. Analysis centered on behavioral risk factors (e.g., sexual networks, wildlife exposure), virologic attributes (e.g., viral clades), and immunologic influences (e.g., vaccination status). Results: The findings reveal distinct regional differences in Mpox transmission dynamics and outcomes. In Africa, zoonotic transmission is prominent, compounded by poor hygiene and under-resourced healthcare systems. In the Americas, outbreaks are driven predominantly by human-to-human transmission within sexual networks, particularly among men who have sex with men (MSM), and international travel. Virologically, the Central African clade demonstrates greater virulence than the West African clade, which has predominated recent global outbreaks. Immunologically, limited smallpox vaccination coverage in younger African populations has increased vulnerability, while partial cross-protection from smallpox vaccines in the Americas has mitigated disease severity to some extent. Conclusion: Effective Mpox control necessitates region-specific public health strategies. Enhanced vaccination programs, improved healthcare infrastructure, and tailored interventions addressing behavioral and virologic drivers are critical. Global collaboration is imperative to mitigate Mpox's spread and burden while addressing socio-economic and epidemiological disparities.